CREATES Act of 2018
USA115th CongressS-974| Senate
| Updated: 6/21/2018
Patrick J. Leahy
Democratic Senator
Vermont
Cosponsors (30)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Dianne Feinstein (Democratic)Richard J. Durbin (Democratic)Mike Lee (Republican)Todd Young (Republican)Angus S. King (Independent)Tom Cotton (Republican)Amy Klobuchar (Democratic)Lindsey Graham (Republican)Rand Paul (Republican)John McCain (Republican)Sheldon Whitehouse (Democratic)Mike Rounds (Republican)Ted Cruz (Republican)Jon Tester (Democratic)Debbie Stabenow (Democratic)John Kennedy (Republican)Deb Fischer (Republican)Claire McCaskill (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Tammy Baldwin (Democratic)Cory A. Booker (Democratic)Robert Menendez (Democratic)Susan M. Collins (Republican)Chuck Grassley (Republican)Steve Daines (Republican)Richard Blumenthal (Democratic)Lisa Murkowski (Republican)
Judiciary Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017 This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S2619)
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 482.
Health
Civil actions and liabilityDrug safety, medical device, and laboratory regulationLicensing and registrationsPrescription drugsProduct development and innovation
CREATES Act of 2018
USA115th CongressS-974| Senate
| Updated: 6/21/2018
Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017 This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S2619)
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 482.
Patrick J. Leahy
Democratic Senator
Vermont
Cosponsors (30)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Dianne Feinstein (Democratic)Richard J. Durbin (Democratic)Mike Lee (Republican)Todd Young (Republican)Angus S. King (Independent)Tom Cotton (Republican)Amy Klobuchar (Democratic)Lindsey Graham (Republican)Rand Paul (Republican)John McCain (Republican)Sheldon Whitehouse (Democratic)Mike Rounds (Republican)Ted Cruz (Republican)Jon Tester (Democratic)Debbie Stabenow (Democratic)John Kennedy (Republican)Deb Fischer (Republican)Claire McCaskill (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Tammy Baldwin (Democratic)Cory A. Booker (Democratic)Robert Menendez (Democratic)Susan M. Collins (Republican)Chuck Grassley (Republican)Steve Daines (Republican)Richard Blumenthal (Democratic)Lisa Murkowski (Republican)
Judiciary Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Civil actions and liabilityDrug safety, medical device, and laboratory regulationLicensing and registrationsPrescription drugsProduct development and innovation